Oral Cholera Vaccine trial successfully completed in Kochi
December 18th, 2010 - 9:05 pm ICT by ANIBy Sankha Ghosh
Kolkata, Dec.18 (ANI): The National Institute for Cholera and Enteric Diseases (NICED) has successfully completed the trial of an Oral Cholera Vaccine (OCV) here on Saturday.
In 2006, the NICED reformulated the composition of a particular double dose OCV, which was produced in Sweden and later in Vietnam.
The Oral Cholera Vaccine named Shanchol has been approved in India, based on the results of a trial on 110,000 human subjects conducted in Kolkata by the NICED.
The Kolkata trials found the Oral Cholera Vaccine provides over 70 percent protection, and additionally, there is no decline in protection for over two years.
The Drug Controller General of India (DCGI), a body which has the sanction of the World Health Organisation (WHO), has approved the vaccine.
“Cholera is a disease of the poor; it does affect higher socio-economic people but mainly it is a disease of the poor and these poor people do not have proper access to water sanitation, proper access to healthcare, and so we think that a vaccine would be very helpful for people like this,” said Dipika Sur, Deputy Director of NICED.
“This vaccine has been produced by internationally recognized Indian manufacturer called Shantha Biotechnics and the vaccine has been named as Shanchol. It is a two-dose vaccine. This vaccine is available commercially but our intension as a research organisation is to bring it into the public health programme, so that the poor people who need it most can have access to it,” she added.
Shanchol was commercially launched in January 2010. Though the vaccine is available at an affordable price, it is yet to be introduced in the public health policy.
“The vaccine is available at an affordable price. Initially, the vaccine which was developed in Sweden was very expensive and we did not want to do the trial with it, but when it was reformulated in Vietnam, it became much less expensive, and that is why we decided that we can take up this project because if this vaccine comes into the market,” said Sur.
Sur further said that NICED is in its fourth year of trial to find out when the booster dose can be given. (ANI)
- Oral vaccine could prevent up to 60pc of cholera cases - Mar 16, 2011
- New oral cholera vaccine holds promise - Apr 10, 2009
- India's Bharat Biotech to sell $1 diarrhoea vaccine - Jun 06, 2011
- Ghana cholera toll rises to 21 - Apr 19, 2012
- New live oral cholera vaccine developed by Indian scientists - Nov 11, 2009
- Special sugar, nanoparticles may help detect cholera toxin - Jan 19, 2011
- Double doses of chicken pox vaccine most effective: Study - Jan 05, 2011
- Study says developing nations biotech firms may be forced to make drugs for rich West - Sep 14, 2010
- Nasal spray flu vaccine one step closer - Feb 18, 2011
- Panel report on HPV vaccine trials slammed - May 09, 2011
- Vaccines for heart attacks to be ready within 5 years - Apr 01, 2012
- Novel vaccine may fight malaria, cholera - Jan 27, 2010
- Pune firm slashes pentavalent vaccine prices 60 percent - Jun 13, 2011
- First vaccine against kala azar ready for trial - Feb 22, 2012
- India to scale up its immunisation programmes: Azad - Aug 02, 2011
Tags: biotechnics, cholera vaccine, composition, controller general, dcgi, decline, deputy director, double dose, enteric diseases, ghosh, human subjects, indian manufacturer, intension, kochi, public health policy, research organisation, sanction, vaccine trial, water sanitation, world health organisation